> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Individualised mRNA melanoma vaccine with pembrolizumab cuts recurrence or death by 42%
- URL: https://www.coios.me/individualised-mrna-melanoma-vaccine-with-pembrolizumab/
- Published: 2026-10-31T11:18:24.000Z
- Updated: 2026-10-31T11:48:24.000Z
- Description: Adding intismeran autogene to pembrolizumab after melanoma was removed reduced recurrence or death risk by 42% in phase III INTerpath-0001.
- Author: Daniel Ryan
- Tags: Tomorrow's world, Innovation in treatment, Cancer, #peer-reviewed, #new, #item, #source-2026-10, #score-80

This news item reports results of the phase III INTerpath-0001 trial in patients whose melanoma had been surgically removed. The trial added intismeran autogene, an individualised mRNA neoantigen vaccine, to the PD-1 inhibitor pembrolizumab. The comparison was against adjuvant pembrolizumab alone. The combination reduced the risk of disease recurrence or death by 42%. The results were presented at the ESMO Congress 2026 in Madrid. The abstract gives no sample size, follow-up time, confidence interval or overall survival data.

*Why it is interesting: An individualised mRNA vaccine shows a 42% reduction in recurrence or death in a phase III adjuvant trial. The vaccine is built from each patient's own tumour neoantigens.*

Source

[Cancer Discovery, 26 October 2026](https://doi.org/10.1158/2159-8290.cd-nw2026-0098?ref=coios.me)

Paper

First mRNA Cancer Vaccine Succeeds in Phase III Trial

DOI

10.1158/2159-8290.cd-nw2026-0098

Type

Peer-reviewed article

Design

News report of a phase III randomised trial (INTerpath-0001) of adjuvant intismeran autogene plus pembrolizumab after melanoma surgery; n and follow-up not stated

Verdict

New finding

Driver

[Innovation in treatment](https://www.coios.me/d-treatment-innovation/)

Driver

[Cancer](https://www.coios.me/d-cancer/)